New from XDx – Announcing…
AlloMap molecular expression testing is now available for cardiac transplants as early as 2 months post cardiac transplant!
For cardiac transplant patients, acute cellular rejection is most worrisome in the first months post transplant.
As of Monday, August 21, 2006, AlloMap molecular expression testing is available to help you monitor patients as early as 2 months post cardiac transplant.
When combined with patient assessment, AlloMap testing can provide the confidence you need to rule out acute cellular rejection.
Freedom from Future Rejection
A CARGO sub-study showed that patients with scores < 20 in the first 6 months post transplant were free from ACR ≥ 3A(2R) for the next 80 days (~12 weeks)
1.
